30 closest matches · ranked by relevance
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Leukemia
Primary: Continuous Complete Remission at 1 Year — 21 participants
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Leukemia
Primary: Complete Response Rate — 89 percentage of patients
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Leukemia
Primary: Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy — 91 percentage of analyzable subjects
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Central Nervous System Leukemia
Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
Leukemia, Acute Lymphoblastic
Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001
Leukemia
Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Leukemia, Myeloid, Acute
Primary: The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine. — 100; NA mg
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Leukemia
Primary: Number of Patients With Complete Remission — 3 participants
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Toxicities — 0 Participants
Leukemia
Primary: Complete Remission — 52 percentage of participants
Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability
Acute Myeloid Leukemia · Leukemia Cutis · Myeloid Neoplasm
Primary: Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations — 45.64; 46.95 percentage of patients
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy — 79.8; 83.2; 66.7 Percent probability